Dr. Bruce Hensel reports on a new study from Cedars Sinai, which found that heart attack patients who received stem cell injections were able to reverse some of the damage to their heart.
Authors of a small study using cardiac-derived stem cells in “convalescent” MI patients say they’ve uncovered some of the first true evidence that the heart can regenerate, describing a new method that, they say, led to “unprecedented” improvements in viable heart muscle.
Results of the CADUCEUS study, published online February 13, 2012 in the Lancet, showed not only that scar size was reduced on MRI at six months—something also seen in previous research—but also that the amount of viable heart mass and regional contractility were also improved.
Dr Raj R Makkar (Cedars-Sinai Heart Institute, Los Angeles, CA) and colleagues used a proprietary technique to harvest autologous heart cells from endomyocardial biopsy specimens, then grow these cells—dubbed cardiosphere-derived-cells—to the therapeutic dose. The test population was made up of post-MI patients with left ventricular ejection fractions (LVEFs) ranging from 25% to 45%, with subjects randomized 2:1 to receive cardiosphere-derived cells (17 patients) or to standard care (eight patients).
Shayne Heffernan
Shayne Heffernan oversees the management of funds for institutions and high net worth individuals.
Shayne Heffernan holds a Ph.D. in Economics and brings with him over 25 years of trading experience in Asia and hands on experience in Venture Capital, he has been involved in several start ups that have seen market capitalization over $500m and 1 that reach a peak market cap of $15b. He has managed and overseen start ups in Mining, Shipping, Technology and Financial Services. www.livetradingnews.com
No comments:
Post a Comment